insulin detemir + insulin glulisine

This is a combination therapy consisting of two recombinant human insulin analogues, insulin detemir and insulin glulisine, used in the management of diabetes mellitus. Insulin detemir is a long-acting (basal) insulin analogue that provides continuous background insulin coverage, while insulin glulisine is a rapid-acting (prandial) analogue designed to control blood glucose spikes around meals. The combination mimics physiological basal-bolus regimens for optimal glycemic control in both type 1 and type 2 diabetes. Insulin detemir acts by binding to the insulin receptor, activating downstream signaling pathways that promote glucose uptake and metabolism; its prolonged action results from slow absorption and strong albumin binding due to its myristic acid side chain[5][2]. Insulin glulisine also binds the same receptor but has rapid onset and short duration due to modifications at specific amino acids, making it suitable for mealtime glucose control[8][4]. This regimen is typically individualized based on patient needs.

Brand names

ApidraLevemir

Other names

none